Navigation Links
Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
Date:2/26/2013

LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Cowen and Company 33rd Annual Healthcare Conference on Tuesday, March 5, 2013 at 8:40 am EST.  The conference is being held at the Boston Marriott Copley Place.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of each webcast will be archived on the Company's website for two weeks following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
2. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
3. Regulus to Present at Two Upcoming Investor Conferences
4. Regulus Appoints Mark G. Foletta to its Board of Directors
5. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
8. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
9. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
10. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
11. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... 19, 2017 Conference Call and Webcast to Follow ... announced it will release results for the fourth quarter of 2016 ... ... conference call at 4:30 PM ET on Wednesday, February 15, 2017, ... 2016 financial results and other corporate activities. To participate in the ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
Breaking Medicine Technology:
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to clear ... when clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s ... Safety Commission for the proper use of snow blowers:, , When ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic ... in order to make it easier for their readers to get the information they ... impact as well as the techniques used on those particular areas. , “We are ...
Breaking Medicine News(10 mins):